2020年

November 27, 2020: Kyorin Pharmaceutical Receives Marketing Approval for injectable New Quinolone Antibacterial Agent "Lasvic® Intravenous Drip Infusion Kit 150mg"
November 5, 2020: Summary of Consolidated Financial Results (For the Second Quarter Ended September 30, 2020) [Japanese Standard]
November 5, 2020: Second Quarter Consolidated Financial Results for the Fiscal Year Ending March 31, 2021 - Supplementary Information
November 5, 2020: The Revision of Consolidated Financial Forecasts for Fiscal Year Ending March 31, 2021
November 2, 2020: Revision of Consolidated Financial Forecasts
October 12, 2020: KYORIN assigns Intellectual Properties regarding KRP-203 to Priothera
September 30, 2020: Notice regarding the joint development and commercialization agreement for [AKP-009], a treatment agent for Benign Prostatic Hyperplasia
August 3, 2020: First Quarter Consolidated Financial Results for the Fiscal Year Ending March 31, 2021 - Supplementary Information
August 3, 2020: Summary of Consolidated Financial Results (For the First Quarter Ending Dec 31, 2021) [Japanese Standard]
August 3, 2020: KYORIN and Otonomy Signed License Agreement for Novel Candidate Compound for Sensorineural Hearing Loss
June 29, 2020: Kyorin Pharmaceutical obtains approval for additional indication for pediatric use of Flutiform® 50 Aerosol, a combination drug for asthma treatment
May 12, 2020: Summary of Consolidated Financial Results (For the fiscal year ended March 31, 2020) [Japanese Standard]
May 12, 2020: Consolidated Financial Results for the Fiscal Year Ending March 31, 2020- Supplementary Information
March 31, 2020: Release of Novel Coronavirus Detection Reagent "SARS-CoV-2 GeneSoC ER Kyorin"
February 5, 2020: Summary of Consolidated Financial Results (For the Third Quarter Ended Dec 31, 2019) [Japanese Standard]
February 5, 2020: Third Quarter Consolidated Financial Results for the Fiscal Year Ending March 31, 2020 - Supplementary Information
January 6, 2020: KYORIN and aTyr to Collaborate on Novel Immunomodulator